Zydus gets USFDA's orphan drug designation for beta-thalassemia product

Zydus Lifesciences announced a significant development for beta-thalassemia patients. The US Food and Drug Administration has granted Orphan Drug Designation to Desidustat. This novel product aims to treat the rare blood disorder. The designation supports the development of medicines for diseases affecting fewer than 2 lakh people in the US.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/ixsU2Vp
via IFTTT